干眼炎症反应机制及抗炎治疗的研究进展

doi:10.6040/j.issn.1673-3770.0.2020.484

摘要/Abstract

摘要： 干眼是一种多因素所致的泪液稳定性和眼表功能损害的疾病,近年来患病率逐渐上升,已成为最常见的眼表疾病之一。炎症反应为干眼发病机制中最为关键的环节,其通过刺激眼表细胞,激活局部免疫反应、导致眼表泪膜稳定性下降、增加泪液渗透压,从而导致局部眼表损伤,该过程中有多种炎症介质和免疫细胞的参与。近年来干眼炎症反应机制的相关研究逐渐增多。就干眼炎症介质、免疫细胞、免疫应答及抗炎治疗进行综述,以期系统性了解干眼炎症反应机制及其临床意义。

关键词: 干眼, 炎症介质, 炎症反应机制, 抗炎, 治疗

Abstract: Dry eye is a multifactorial disease of the tear film and ocular surface. In recent years, it has become one of the most common ocular surface diseases, with its prevalence increasing every year. Inflammation plays a key role in the pathogenesis of dry eye. It can stimulate ocular surface cells, activate the local immune response, lead to unstable tear films, increase the osmolality of tears, and then cause local ocular surface damage. Multiple inflammatory mediators and immune cells participate in the development of dry eye. There is increasing research on the inflammatory reaction involved in dry eye, and this paper reviews the inflammatory mediators, immune cells, immune response, and anti-inflammatory treatments to systematically understand the inflammatory reaction mechanism of dry eye and its clinical significance.

Key words: Dry eye, Inflammatory mediator, Inflammatory reaction, Anti-inflammation, Treatment

中图分类号:

R777.34

狄宇，李莹. 干眼炎症反应机制及抗炎治疗的研究进展[J]. 山东大学耳鼻喉眼学报, 2022, 36(2): 144-150.

DI Yu,LI Ying. Research progress in the inflammatory reaction and anti-inflammatory treatments in dry eye[J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2022, 36(2): 144-150.

参考文献

[1] Periman LM, Perez VL, Saban DR, et al. The immunological basis of dry eye disease and current topical treatment options[J]. J Ocul Pharmacol Ther, 2020, 36(3): 137-146. doi:10.1089/jop.2019.0060.
[2] Craig JP, Nichols KK, Akpek EK, et al. TFOS DEWS II definition and classification report[J]. Ocul Surf, 2017, 15(3): 276-283. doi:10.1016/j.jtos.2017.05.008.
[3] Stern ME, Schaumburg CS, Pflugfelder SC. Dry eye as a mucosal autoimmune disease[J]. Int Rev Immunol, 2013, 32(1): 19-41. doi:10.3109/08830185.2012.748052.
[4] 孙子雯, 崔洪玮, 孙喜灵, 等. 干眼病的病因、发病机制及治疗进展[J]. 山东大学耳鼻喉眼学报, 2019, 3(33):159-166. doi: 10.6040/j.issn.1673-3770.0.2018.411. SUN Ziwen, CUI Hongwei, SUN Xiling, et al. Etiology, pathogenesis, and management of dry eye[J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2019, 3(33):159-166. doi: 10.6040/j.issn.1673-3770.0.2018.411.
[5] Yagci A, Gurdal C. The role and treatment of inflammation in dry eye disease[J]. Int Ophthalmol, 2014, 34(6): 1291-1301. doi:10.1007/s10792-014-9969-x.
[6] 高雅, 李冰, 陈研遐, 等. 白介素1β在干眼患者眼表的表达[J]. 中华眼视光学与视觉科学杂志, 2014, 16(4): 228-232. doi: 10.3760/cma.j.issn.1674-845X.2014.04.009. GAO Ya, LI Bing, CHEN Yanxia, et al. A study of the expression of IL-1 beta on the ocular surface in dry eye patients[J]. Chinese Journal of Optometry & Ophthalmology, 2014, 16(4): 228-232. doi: 10.3760/cma.j.issn.1674-845X.2014.04.009.
[7] Benitez J, Cantu-Dibildox J, Sanz-González SM, et al. Cytokine expression in tears of patients with Glaucoma or dry eye disease: a prospective, observational cohort study[J]. Eur J Ophthalmol, 2019, 29(4): 437-443. doi:10.1177/1120672118795399.
[8] Landsend ECS, Utheim A, Pedersen HR, et al. The level of inflammatory tear cytokines is elevated in congenital aniridia and associated with meibomian gland dysfunction[J]. Invest Ophthalmol Vis Sci, 2018, 59(5): 2197-2204. doi:10.1167/iovs.18-24027.
[9] Lee H, Chung B, Kim KS, et al. Effects of topical loteprednol etabonate on tear cytokines and clinical outcomes in moderate and severe meibomian gland dysfunction: randomized clinical trial[J]. Am J Ophthalmol, 2014, 158(6): 1172-1183.e1. doi:10.1016/j.ajo.2014.08.015.
[10] Bi Y, Yang R. Direct and indirect regulatory mechanisms in TH17 cell differentiation and functions[J]. Scand J Immunol, 2012, 75(6): 543-552. doi:10.1111/j.1365-3083.2012.02686.x.
[11] Higuchi A, Kawakita T, Tsubota K. IL-6 induction in desiccated corneal epithelium in vitro and in vivo[J]. Mol Vis, 2011, 17: 2400-2406. doi: 10.2214/ajr.142.6.1205.
[12] Na KS, Mok JW, Kim JY, et al. Correlations between tear cytokines, chemokines, and soluble receptors and clinical severity of dry eye disease[J]. Invest Ophthalmol Vis Sci, 2012, 53(9): 5443-5450. doi:10.1167/iovs.11-9417.
[13] McDonnell PJ, Pflugfelder SC, Stern ME, et al. Study design and baseline findings from the progression of ocular findings(PROOF)natural history study of dry eye[J]. BMC Ophthalmol, 2017, 17(1): 265. doi:10.1186/s12886-017-0646-5.
[14] Jung JW, Han SJ, Nam SM, et al. Meibomian gland dysfunction and tear cytokines after cataract surgery according to preoperative meibomian gland status[J]. Clin Exp Ophthalmol, 2016, 44(7): 555-562. doi:10.1111/ceo.12744.
[15] De Paiva CS, Chotikavanich S, Pangelinan SB, et al. IL-17 disrupts corneal barrier following desiccating stress[J]. Mucosal Immunol, 2009, 2(3): 243-253. doi:10.1038/mi.2009.5.
[16] Chen Y, Chauhan SK, Lee HS, et al. Chronic dry eye disease is principally mediated by effector memory Th17 cells[J]. Mucosal Immunol, 2014, 7(1): 38-45. doi:10.1038/mi.2013.20.
[17] Lee SY, Han SJ, Nam SM, et al. Analysis of tear cytokines and clinical correlations in sjögren syndrome dry eye patients and non-sjögren syndrome dry eye patients[J]. Am J Ophthalmol, 2013, 156(2): 247-253. doi:10.1016/j.ajo.2013.04.003.
[18] Mrugacz M, Ostrowska L, Bryl A, et al. Pro-inflammatory cytokines associated with clinical severity of dry eye disease of patients with depression[J]. Adv Med Sci, 2017, 62(2): 338-344. doi:10.1016/j.advms.2017.03.003.
[19] Tong L, Beuerman R, Simonyi S, et al. Effects of punctal occlusion on clinical signs and symptoms and on tear cytokine levels in patients with dry eye[J]. Ocul Surf, 2016, 14(2): 233-241. doi:10.1016/j.jtos.2015.12.004.
[20] Pflugfelder SC, De Paiva CS, Moore QL, et al. Aqueous tear deficiency increases conjunctival interferon-γ(IFN-γ)expression and goblet cell loss[J]. Invest Ophthalmol Vis Sci, 2015, 56(12): 7545-7550. doi:10.1167/iovs.15-17627.
[21] Jackson DC, Zeng W, Wong CY, et al. Tear interferon-gamma as a biomarker for evaporative dry eye disease[J]. Invest Ophthalmol Vis Sci, 2016, 57(11): 4824-4830. doi:10.1167/iovs.16-19757.
[22] Chotikavanich S, de Paiva CS, Li DQ, et al. Production and activity of matrix metalloproteinase-9 on the ocular surface increase in dysfunctional tear syndrome[J]. Invest Ophthalmol Vis Sci, 2009, 50(7): 3203-3209. doi:10.1167/iovs.08-2476.
[23] Yang S, Lee HJ, Kim DY, et al. The use of conjunctival staining to measure ocular surface inflammation in patients with dry eye[J]. Cornea, 2019, 38(6): 698-705. doi:10.1097/ico.0000000000001916.
[24] Messmer EM, von Lindenfels V, Garbe A, et al. Matrix metalloproteinase 9 testing in dry eye disease using a commercially available point-of-care immunoassay[J]. Ophthalmology, 2016, 123(11): 2300-2308. doi:10.1016/j.ophtha.2016.07.028.
[25] Schargus M, Ivanova S, Kakkassery V, et al. Correlation of tear film osmolarity and 2 different MMP-9 tests with common dry eye tests in a cohort of non-dry eye patients[J]. Cornea, 2015, 34(7): 739-744. doi:10.1097/ico.0000000000000449.
[26] Enríquez-de-Salamanca A, Castellanos E, Stern ME, et al. Tear cytokine and chemokine analysis and clinical correlations in evaporative-type dry eye disease[J]. Mol Vis, 2010, 16: 862-873. PMID: 20508732.
[27] Massingale ML, Li XH, Vallabhajosyula M, et al. Analysis of inflammatory cytokines in the tears of dry eye patients[J]. Cornea, 2009, 28(9): 1023-1027. doi:10.1097/ico.0b013e3181a16578.
[28] Choi W, Li ZR, Oh HJ, et al. Expression of CCR5 and its ligands CCL3, -4, and -5 in the tear film and ocular surface of patients with dry eye disease[J]. Curr Eye Res, 2012, 37(1): 12-17. doi:10.3109/02713683.2011.622852.
[29] Nicolle P, Liang H, Reboussin E, et al. Proinflammatory markers, chemokines, and enkephalin in patients suffering from dry eye disease[J]. Int J Mol Sci, 2018, 19(4): 1221. doi:10.3390/ijms19041221.
[30] Wang T, Li WH, Cheng HH, et al. The important role of the chemokine axis CCR7-CCL19 and CCR7-CCL21 in the pathophysiology of the immuno-inflammatory response in dry eye disease[J]. Ocular Immunol Inflamm, 2019: 1-12. doi:10.1080/09273948.2019.1674891.
[31] Lefort CT, Ley K. Neutrophil arrest by LFA-1 activation[J]. Front Immunol, 2012, 3: 157. doi:10.3389/fimmu.2012.00157.
[32] Hogg N, Laschinger M, Giles K, et al. T-cell integrins: more than just sticking points[J]. J Cell Sci, 2003, 116(Pt 23): 4695-4705. doi:10.1242/jcs.00876.
[33] Liu M, Gao H, Wang T, et al. An essential role for dendritic cells in vernal keratoconjunctivitis: analysis by laser scanning confocal microscopy[J]. Clin Exp Allergy, 2014, 44(3): 362-370. doi:10.1111/cea.12264.
[34] Hamrah P, Huq SO, Liu Y, et al. Corneal immunity is mediated by heterogeneous population of antigen-presenting cells[J]. J Leukoc Biol, 2003, 74(2): 172-178. doi:10.1189/jlb.1102544.
[35] El Annan J, Chauhan SK, Ecoiffier T, et al. Characterization of effector T cells in dry eye disease[J]. Invest Ophthalmol Vis Sci, 2009, 50(8): 3802-3807. doi:10.1167/iovs.08-2417.
[36] De Paiva CS, Villarreal AL, Corrales RM, et al. Dry eye-induced conjunctival epithelial squamous Metaplasia is modulated by interferon-gamma[J]. Invest Ophthalmol Vis Sci, 2007, 48(6): 2553-2560. doi:10.1167/iovs.07-0069.
[37] Chauhan SK, El Annan J, Ecoiffier T, et al. Autoimmunity in dry eye is due to resistance of Th17 to Treg suppression[J]. J Immunol, 2009, 182(3): 1247-1252. doi:10.4049/jimmunol.182.3.1247.
[38] von Knethen A, Heinicke U, Weigert A, et al. Histone deacetylation inhibitors as modulators of regulatory T cells[J]. Int J Mol Sci, 2020, 21(7): 2356. doi:10.3390/ijms21072356.
[39] Ratay ML, Balmert SC, Bassin EJ, et al. Controlled release of an HDAC inhibitor for reduction of inflammation in dry eye disease[J]. Acta Biomater, 2018, 71: 261-270. doi:10.1016/j.actbio.2018.03.002.
[40] 蔡丽萍, 张宏. 炎症免疫相关信号通路在干眼发病机制中的研究进展[J]. 国际眼科杂志, 2016, 16(6): 1084-1088. doi:10.3980/j.issn.1672-5123.2016.6.20. LIPING Cai, HONG Zhang. Research progress on inflammatory immunity related signaling pathway for the pathogenesis of dry eye[J]. Int Eye Sci, 2016, 16(6): 1084-1088. doi:10.3980/j.issn.1672-5123.2016.6.20.
[41] Hattori T, Takahashi H, Dana R. Novel insights into the immunoregulatory function and localization of dendritic cells[J]. Cornea, 2016, 35(Suppl 1): S49-S54. doi:10.1097/ico.0000000000001005.
[42] Pflugfelder SC, Corrales RM, de Paiva CS. T helper cytokines in dry eye disease[J]. Exp Eye Res, 2013, 117: 118-125. doi:10.1016/j.exer.2013.08.013.
[43] Pflugfelder SC, Geerling G, Kinoshita S, et al. Management and therapy of dry eye disease: Report of the management and therapy subcommittee of the international Dry Eye WorkShop(2007)[C] //2007, 5: 163-178.
[44] Pinto-Fraga J, Lopez-Miguel A, Gonzalez-Garcia MJ, et al. Topical fluorometholone protects the ocular surface of dry eye patients from desiccating stress: a randomized controlled clinical trial[J]. Ophthalmology, 2016, 123(1):141-53. doi: 10.1016/j.ophtha.2015.09.029.
[45] Jung HH, Ji YS, Sung MS, et al. Long-term outcome of treatment with topical corticosteroids for severe dry eye associated with sjögren's syndrome[J]. Chonnam Med J, 2015, 51(1): 26-32. doi:10.4068/cmj.2015.51.1.26.
[46] Sall K, Stevenson OD, Mundorf TK, et al. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease[J]. Ophthalmology, 2000, 107(4): 631-639. doi:10.1016/S0161-6420(99)00176-1.
[47] Ji YW, Kim HM, Ryu SY, et al. Changes in human tear proteome following topical treatment of dry eye disease: cyclosporine A versus diquafosol tetrasodium[J]. Invest Ophthalmol Vis Sci, 2019, 60(15): 5035-5044. doi:10.1167/iovs.19-27872.
[48] Daull P, Barabino S, Feraille L, et al. Modulation of inflammation-related genes in the cornea of a mouse model of dry eye upon treatment with cyclosporine eye drops[J]. Curr Eye Res, 2019, 44(5): 476-485. doi:10.1080/02713683.2018.1563197.
[49] Guimaraes de Souza R, Yu Z, Stern ME, et al. Suppression of Th1-mediated keratoconjunctivitis sicca by lifitegrast[J]. J Ocul Pharmacol Ther, 2018, 34(7): 543-549. doi:10.1089/jop.2018.0047.
[50] Haber SL, Benson V, Buckway CJ, et al. Lifitegrast: a novel drug for patients with dry eye disease[J]. Ther Adv Ophthalmol, 2019, 11: 2515841419870366. doi:10.1177/2515841419870366.
[51] Semba CP, Torkildsen GL, Lonsdale JD, et al. A phase 2 randomized, double-masked, placebo-controlled study of a novel integrin antagonist(SAR 1118)for the treatment of dry eye[J]. Am J Ophthalmol, 2012, 153(6): 1050-1060.e1. doi:10.1016/j.ajo.2011.11.003.
[52] Holland EJ, Luchs J, Karpecki PM, et al. Lifitegrast for the treatment of dry eye disease: results of a phase Ⅲ, randomized, double-masked, placebo-controlled trial(OPUS-3)[J]. Ophthalmology, 2017, 124(1): 53-60. doi:10.1016/j.ophtha.2016.09.025.
[53] Kim CE, Kleinman HK, Sosne G, et al. RGN-259(thymosin β4)improves clinically important dry eye efficacies in comparison with prescription drugs in a dry eye model[J]. Sci Rep, 2018, 8(1): 1-14. doi:10.1038/s41598-018-28861-5.
[54] Sosne G, Dunn SP, Kim C. Thymosin β4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial[J]. Cornea, 2015, 34(5): 491-496. doi:10.1097/ico.0000000000000379.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed